Akashi Therapeutics

Akashi Therapeutics is a clinical stage biotechnology company based in Cambridge, Massachusetts, with a team of 5 to 9 employees. The company focuses on developing innovative treatments for Duchenne muscular dystrophy and other rare diseases. Akashi Therapeutics is dedicated to improving the lives of patients with debilitating diseases through its portfolio of therapeutic products. Its lead clinical asset, HT-100, is a drug candidate that exhibits potent anti-inflammatory and anti-fibrotic properties while promoting healthy muscle regeneration. The company's second clinical candidate, DT-200, is a Selective Androgen Receptor Modulator (SARM) designed to build muscle mass and strength. Akashi Therapeutics was formed through the merger of Halo Therapeutics and Dart Therapeutics, a unique collaboration between patient advocacy organizations and seasoned biotechnology industry professionals. This partnership combines the passion of patient communities with the expertise of experienced drug developers, driving the company's dedication to finding effective therapies for rare diseases. For more information about Akashi Therapeutics and its groundbreaking work, please visit their website at akashirx.com.